Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis
CHEST · 2025
DOI: 10.1016/j.chest.2025.04.003 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift CHEST, 2025. Verfasst von Michael Kreuter und 8 weiteren Autor:innen. Beteiligte Einrichtung: Mainz Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center, Mainz, Germany; Pulmonary, Critical Care & Sleep Medi…. Hauptthemen laut MEDLINE: Receptors, Lysophosphatidic Acid, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb, Bristol-Myers Squibb Co.
Abstract (Originalsprache)
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are chronic fibrosing interstitial lung diseases associated with irreversible loss of lung function and early mortality. Admilparant (BMS-986278) is an oral lysophosphatidic acid receptor 1 antagonist under development for treatment of IPF and PPF. RESEARCH QUESTION: How does admilparant affect time to disease progression in patients with IPF or PPF? STUDY DESIGN AND METHODS: In a phase 2, randomized, double-anonymized, placebo-controlled study, parallel cohorts of patients with IPF or PPF were randomized separately 1:1:1 to receive 30 mg admilparant, 60 mg admilparant, or placebo twice daily for 26 weeks; background antifibrotics were allowed. The effect of admilparant vs placebo on time to disease progression was assessed post hoc. Disease progression was defined as a composite of relative decline of ≥ 10% in percent predicted FVC (ppFVC), acute exacerbation, all-cause hospitalization, and all-cause mortality. Subgroup analyses were performed based on median ppFVC at baseline. A Kaplan-Meier product-limit approach assessed time to first event of disease progression over 26 weeks. RESULTS: In total, 255 patients with IPF and 114 patients with PPF were included. Median ppFVC at baseline was 77.3% and 64.7% in the IPF and PPF cohorts, respectively. Treatment with 60 mg admilparant delayed time to disease progression over 26 weeks compared with placebo in both cohorts of patients (IPF: hazard ratio, 0.54; 95% CI, 0.31-0.95; PPF: hazard ratio, 0.41; 95% CI, 0.18-0.90). A similar trend was observed in the subgroup analysis of patients with ppFVC at baseline either below or above the median value. In both cohorts, the most frequent first event was relative decline of ≥ 10% in ppFVC; no deaths were reported as first progression events. INTERPRETATION: These findings support further evaluation of admilparant as a therapeutic option for patients with IPF or PPF in phase 3 trials. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT04308681; URL: www. CLINICALTRIALS: gov.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mainz Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center, Mainz, Germany; Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany. Electronic address: kre…
- University of Southern California, Los Angeles, CA; National Heart and Lung Institute, Imperial College, London, England.
- Department of Pulmonology, University Hospitals Leuven, Leuven, Belgium.
- ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, University Autonomade Madrid, Madrid, Spain.
- Pulmonary and Critical Care Medicine, University of Kansas Medical Center, Kansas City, KS.
- Bristol Myers Squibb, Princeton, NJ.
Förderung
- Bristol-Myers Squibb
- Bristol-Myers Squibb Co
Zitieren
APA
Kreuter, M., Maher, T. M., Wuyts, W. A., Valenzuela, C., Hamblin, M., Kim, S., Patel, A., Elpers, B., & Richeldi, L. (2025). Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis. CHEST. https://doi.org/10.1016/j.chest.2025.04.003
Vancouver
Kreuter M, Maher TM, Wuyts WA, Valenzuela C, Hamblin M, Kim S, et al. Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis. CHEST. 2025. doi:10.1016/j.chest.2025.04.003
BibTeX
@article{Kreuter2025,
author = {Kreuter, Michael and Maher, Toby M and Wuyts, Wim A and Valenzuela, Claudia and Hamblin, Mark and Kim, Sinae and Patel, Aditya and Elpers, Brandon and Richeldi, Luca},
title = {Effect of Admilparant, a Lysophosphatidic Acid Receptor 1 Antagonist, on Disease Progression in Pulmonary Fibrosis},
journal = {CHEST},
year = {2025},
doi = {10.1016/j.chest.2025.04.003}
}
EUVIMED